Learn about our comprehensive antibody validation methods to ensure monospecificity.  Antibody Validation>>

Lung Cancer Antibodies

Lung cancer primarily encompasses non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), each with unique characteristics and implications for patient management. Techniques including Western blots, ELISA, flow cytometry, co-immunoprecipitation, and immunohistochemistry can distinguish among the different types of lung cancer and provide vital information about cell proliferation and disease progression, which is critical for the early detection, prognosis/monitoring, and treatment of the disease.

NeoBiotechnologies proudly offers a comprehensive selection of antibodies for lung cancer research (see the table below), with a particular emphasis on IHC-validated antibodies. Our antibodies targeting lung cancer protein markers are rigorously validated for specificity, ensuring precise and reliable results.

Notable lung cancer protein markers:

  • Epidermal Growth Factor Receptor (EGFR): EGFR mutations or overexpression are common in non-small cell lung cancer (NSCLC). Targeted therapies, such as tyrosine kinase inhibitors (TKIs), are used for patients with EGFR mutations.
  • ALK (Anaplastic Lymphoma Kinase): ALK rearrangements are found in a subset of NSCLC cases. Targeted therapies like crizotinib are used to treat ALK-positive lung cancer.
  • ROS1 (c-ros oncogene 1): ROS1 rearrangements are another targetable alteration in NSCLC. Crizotinib and other ALK/ROS1 inhibitors are used in treatment.
  • PD-L1 (Programmed Death-Ligand 1): PD-L1 expression on tumor cells can indicate potential responsiveness to immune checkpoint inhibitors, such as pembrolizumab and nivolumab, for advanced NSCLC.
  • KRAS (Kirsten Rat Sarcoma viral oncogene homolog): KRAS mutations are common in lung cancer, especially in adenocarcinoma. They can influence prognosis and treatment decisions.
  • p53 (Tumor Protein 53): TP53 mutations are found in many lung cancers and may be associated with a worse prognosis.
  • RET (Rearranged During Transfection): RET fusions are a targetable alteration in NSCLC, and specific inhibitors like selpercatinib and pralsetinib are used in treatment.
  • BRAF (v-Raf murine sarcoma viral oncogene homolog B1): BRAF V600E mutations are found in some NSCLC cases and can be targeted with therapies like dabrafenib and trametinib.
  • NTRK (Neurotrophic Tyrosine Kinase Receptor): NTRK fusions are rare but actionable alterations in NSCLC, and larotrectinib and entrectinib are used for treatment.
  • Squamous Cell Carcinoma Antigen (SCCA): a marker used for squamous cell carcinoma, a subtype of NSCLC.
  • TTF-1 (Thyroid Transcription Factor-1): an immunohistochemical marker that can help identify lung adenocarcinomas and other tumors of lung origin.
  • CEA (Carcinoembryonic Antigen): levels can be elevated in lung cancer, and this marker is often used for monitoring treatment response and disease recurrence.
  • MUC1 (Mucin 1): a protein overexpressed in many lung cancers, particularly adenocarcinomas.
  • ProGRP (Pro-Gastrin-Releasing Peptide): a marker for small cell lung cancer (SCLC) and can be used for diagnosis and monitoring.
  • NSE (Neuron-Specific Enolase): a general marker used in SCLC cases and can be indicative of the tumor burden.
  • Chromogranin A: a marker for neuroendocrine tumors, including SCLC.

Showing 1–25 of 214 results

Lung Cancer

Showing 1–25 of 214 results


We hold Exclusive rights to 10,000 recombinant and hybridoma antibody products, available for Licensing or Collaboration.